Using a novel Enpp1 inhibitor that can be delivered orally and results in on-target inhibition of Enpp1 activity in mice, we demonstrate that Enpp1-targeted therapy improves tumor control by radiation therapy in these cancers. Here, ENPP1 is linked to neoplasm.